Over the past few years, the pharmaceutical industry has been embroiled in controversy over access to clinical trial data. At issue is the ability for researchers to independently verify study results and, consequently, improve patient treatments that can lead to better health and lower costs.. This sentiment has accelerated in light of various safety scandals that revealed data for some drugs was never fully published or disclosed. In response, a few drug makers – including GlaxoSmithKline and Johnson & Johnson – have recently proposed differing plans for providing access, although the extent to which their efforts will assuage concerns remains to be seen.. We spoke with Peter Doshi, an assistant professor of pharmaceutical health services research at the University of Maryland School of Pharmacy and an associate editor at the British Medical Journal, who has been at the forefront of a campaign to prod drug makers to move faster.. The full Q&A, after the jump…